Ambrisentan

General information

Ambrisentan is an endothelin receptor antagonist that has been investigated in the treatment of idiopathic and secondary pulmonary hypertension [ ]. It is a propionic acid-based selective antagonist at endothelin type A (ET _A ) receptors. It is licensed for the treatment of some types of pulmonary hypertension under specialist supervision. Raised liver enzymes have been seen with bosentan and other drugs in this class. Animal studies and clinical trials have been reviewed [ ], as has the role of ambrisentan in the treatment of pulmonary artery hypertension [ ]. Both of these reviews discuss the safety implications of ambrisentan treatment, particularly with respect to potential liver injury, because of the finding of raised aminotransferase activities in clinical trials and the need for monitoring during therapy. Its common adverse effects include peripheral edema, nasal congestion, headache, dizziness, and a fall in hemoglobin concentration.

Drug studies